> Details

Yao, Chunxia; Veleva, Tina; Scott, Larry; Cao, Shuyi; Li, Luge; Chen, Gong; Jeyabal, Prince; Pan, Xiaolu; Alsina, Katherina M.; Abu-Taha, Issam; Ghezelbash, Shokoufeh; Reynolds, Corey L.; Shen, Ying H.; LeMaire, Scott A.; Schmitz, Wilhelm; Müller, Frank U.; El-Armouche, Ali; Tony Eissa, N.; Beeton, Christine; Nattel, Stanley; Wehrens, Xander H.T.; Dobrev, Dobromir; Li, Na

Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation
  • Contributor: Yao, Chunxia; Veleva, Tina; Scott, Larry; Cao, Shuyi; Li, Luge; Chen, Gong; Jeyabal, Prince; Pan, Xiaolu; Alsina, Katherina M.; Abu-Taha, Issam; Ghezelbash, Shokoufeh; Reynolds, Corey L.; Shen, Ying H.; LeMaire, Scott A.; Schmitz, Wilhelm; Müller, Frank U.; El-Armouche, Ali; Tony Eissa, N.; Beeton, Christine; Nattel, Stanley; Wehrens, Xander H.T.; Dobrev, Dobromir; Li, Na
  • Published: Ovid Technologies (Wolters Kluwer Health), 2018
  • Published in: Circulation, 138 (2018) 20, Seite 2227-2242
  • Language: English
  • DOI: 10.1161/circulationaha.118.035202
  • ISSN: 0009-7322; 1524-4539
  • Origination:
  • Footnote:
  • Description: Background: Atrial fibrillation (AF) is frequently associated with enhanced inflammatory response. The NLRP3 (NACHT, LRR, and PYD domain containing protein 3) inflammasome mediates caspase-1 activation and interleukin-1β release in immune cells but is not known to play a role in cardiomyocytes (CMs). Here, we assessed the role of CM NLRP3 inflammasome in AF. Methods: NLRP3 inflammasome activation was assessed by immunoblot in atrial whole-tissue lysates and CMs from patients with paroxysmal AF or long-standing persistent (chronic) AF. To determine whether CM-specific activation of NLPR3 is sufficient to promote AF, a CM-specific knockin mouse model expressing constitutively active NLRP3 (CM-KI) was established. In vivo electrophysiology was used to assess atrial arrhythmia vulnerability. To evaluate the mechanism of AF, electric activation pattern, Ca 2+ spark frequency, atrial effective refractory period, and morphology of atria were evaluated in CM-KI mice and wild-type littermates. Results: NLRP3 inflammasome activity was increased in the atrial CMs of patients with paroxysmal AF and chronic AF. CM-KI mice developed spontaneous premature atrial contractions and inducible AF, which was attenuated by a specific NLRP3 inflammasome inhibitor, MCC950. CM-KI mice exhibited ectopic activity, abnormal sarcoplasmic reticulum Ca 2+ release, atrial effective refractory period shortening, and atrial hypertrophy. Adeno-associated virus subtype-9–mediated CM-specific knockdown of Nlrp3 suppressed AF development in CM-KI mice. Finally, genetic inhibition of Nlrp3 prevented AF development in CREM transgenic mice, a well-characterized mouse model of spontaneous AF. Conclusions: Our study establishes a novel pathophysiological role for CM NLRP3 inflammasome signaling, with a mechanistic link to the pathogenesis of AF, and establishes the inhibition of NLRP3 as a potential novel AF therapy approach.
  • Access State: Open Access